Ascendia Pharma, headquartered in New Jersey, United States, is a specialty pharmaceutical company founded in 2012. Specializing in enhanced formulations of existing drug products and enabling formulations for pre-clinical and clinical-stage drug candidates, Ascendia focuses on creating innovative solutions to challenging drug delivery problems and advancing medicines. Their expertise lies in finding effective drug delivery methods for poorly water-soluble molecules, offering comprehensive capabilities to optimize drug product formulation before expensive clinical development. Ascendia provides tailored formulation solutions for rapid compound advancement from discovery to clinical testing, including nano-emulsion, amorphous solid
Ascendia Pharma, headquartered in New Jersey, United States, is a specialty pharmaceutical company founded in 2012. Specializing in enhanced formulations of existing drug products and enabling formulations for pre-clinical and clinical-stage drug candidates, Ascendia focuses on creating innovative solutions to challenging drug delivery problems and advancing medicines. Their expertise lies in finding effective drug delivery methods for poorly water-soluble molecules, offering comprehensive capabilities to optimize drug product formulation before expensive clinical development. Ascendia provides tailored formulation solutions for rapid compound advancement from discovery to clinical testing, including nano-emulsion, amorphous solid dispersion, controlled release, and nano-particle engineering approaches. Additionally, Ascendia is dedicated to life-cycle management and 505(b)(2) product development, focusing on solubility and bioavailability enhancement for difficult-to-formulate compounds. They develop oral, topical, and injectable products, often entering licensing arrangements for co-development. Ascendia also offers cGMP manufacturing services for clinical trial materials, transitioning development programs quickly from formulation selection and optimization to manufacturing for oral, topical, or parenteral administration. They provide manufacturing services to third parties in need of a CDMO partner for their formulation as it moves from pre-clinical phases to early clinical development.
.svg)